Dr. Daniel E. Morganstern, MD

Dr. Morganstern practices at Hartford Hospital in Hartford, Connecticut, part of Hartford HealthCare.

Dr. Morganstern's NPI, 1003986852, was assigned on November 9, 2006. Dr. Morganstern holds Connecticut license 060103.

Dr. Morganstern's primary practice is Hartford Hospital, at 80 Seymour Street, Hartford, CT 06102 in Hartford County. The practice phone is (860) 545-5000.

Dr. Morganstern's primary practice is Hartford Hospital in Hartford, Connecticut, part of Hartford HealthCare. Dr. Morganstern is also affiliated with The Hospital of Central Connecticut. The medical group on file is Hartford Hospital. Dmand AI also links Dr. Morganstern to 1 more hospital, 5 medical groups and 2 group practices and clinics, each named with a free account. Dr. Morganstern's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Morganstern practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Morganstern's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Morganstern is licensed in Connecticut.

CMS data shows 345 Medicare services from Dr. Morganstern across 5 procedure codes in 2024, for 194 Medicare patients. Medicare paid $28,030 for them.

CMS counts 194 Medicare patients who saw Dr. Morganstern in 2024. The largest group is 65 to 74, with 98 patients. 75% of them have cancer, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Morganstern's median patient age at 64, with 93% women.

In 2024, Dr. Morganstern wrote 1,096 Medicare Part D claims for 294 patients. 91% of them were for generic drugs. CMS names the drug for 916 of them, across 13 drugs with 11 or more claims each, at $418,259 in total drug cost. In 2023, CMS named 733 claims across 11 drugs.

Dr. Morganstern accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Morganstern as offering telehealth.

Dmand AI links 7 papers to Dr. Morganstern, published from 2013 to 2020. 2019 was the busiest year, with 2. The most frequent topics are Breast Neoplasms, Capecitabine and Fluorouracil. Dr. Morganstern's most frequent co-authors are Judy Ellen Garber, MD, Jennifer R. Bellon, MD and Brittany L. Bychkovsky, MD.

Dmand AI links Dr. Morganstern to 2 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Breast Carcinoma In Situ, Carcinoma, Lobular and Carcinoma, Ductal, Breast.

CMS Open Payments shows 291 general payments to Dr. Morganstern from 43 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 43% of the total. Novartis Pharmaceuticals Corporation paid the most, $5,328.